Vulvar Paget Disease

Comprehensive Clinical Guide: Vulvar Paget Disease (VPD)

1. Introduction and Clinical Overview

Vulvar Paget Disease (VPD) is a rare, intraepithelial, slow-growing adenocarcinoma of the vulva. It is a cutaneous manifestation of neoplastic cells that typically originate from the underlying epidermis or adnexal structures (primary VPD) or, less commonly, represent an extension of an underlying internal malignancy, such as colorectal or urothelial carcinoma (secondary VPD).

Characterized by its persistent, eczematous, and pruritic nature, VPD often presents a diagnostic challenge due to its morphological mimicry of common inflammatory dermatoses. Because the disease is associated with a high rate of recurrence and, in some cases, progression to invasive carcinoma, early recognition and histological confirmation are paramount for clinical management.

2. Etiology and Pathophysiology

The pathogenesis of Vulvar Paget Disease is categorized into two distinct clinical entities based on the origin of the malignant cells.

Primary Vulvar Paget Disease

Primary VPD is thought to arise from multipotent stem cells within the epidermis or the adnexal structures (apocrine glands). It is strictly intraepithelial at onset (Paget’s disease in situ) but possesses the potential for dermal invasion.

Secondary Vulvar Paget Disease

Secondary VPD occurs when malignant cells from an adjacent internal malignancy migrate into the vulvar epidermis. Common sources include:
* Colorectal Carcinoma: The most frequent source of secondary VPD.
* Urothelial Carcinoma: Often arising from the bladder or urethra.
* Cervical or Endometrial Adenocarcinoma: Less frequent but clinically significant.

Pathophysiological Mechanisms

The hallmark of the disease is the presence of Paget cells. These are large, pale-staining cells with abundant, vacuolated cytoplasm containing mucin (PAS-positive, diastase-resistant). These cells infiltrate the squamous epithelium individually or in small clusters (pagetoid spread).

3. Clinical Presentation and Staging

Standard Presentation

Patients typically present in the post-menopausal years (mean age 65–70). The clinical appearance is often described as "red, raw, and weeping."

• Symptoms: Intense pruritus, burning, soreness, and occasional bleeding.
• Physical Findings:
  • Erythematous, well-demarcated plaques.
  • "Crusty" or eczematous surface changes.
  • White, hyperkeratotic islands (islands of white epithelium).
  • Skin thickening or ulceration in advanced cases.

Clinical Staging (Wilkinson and Brown Classification)

While no universally accepted staging system exists, the Wilkinson and Brown classification is widely used to categorize the disease:

1. Type 1 (Primary):
   • 1a: Intraepithelial VPD without underlying malignancy.
   • 1b: Intraepithelial VPD with underlying adnexal adenocarcinoma.
   • 1c: Intraepithelial VPD with invasive adnexal adenocarcinoma.
2. Type 2 (Secondary):
   • 2a: VPD associated with primary anorectal adenocarcinoma.
   • 2b: VPD associated with primary urothelial adenocarcinoma.

4. Diagnostic Workup and Differential Diagnosis

Key Diagnostic Tests

1. Biopsy: The gold standard. Multiple punch biopsies are mandatory as the disease is often multifocal.
2. Immunohistochemistry (IHC): Essential for differentiating primary from secondary VPD.
   • Primary: CK7 positive, CK20 negative, GCDFP-15 positive.
   • Secondary (Colorectal): CK7 negative, CK20 positive, CDX2 positive.
3. Systemic Imaging: If secondary VPD is suspected, workup must include colonoscopy, cystoscopy, and pelvic imaging (CT/MRI) to rule out internal malignancies.

Differential Diagnosis

VPD is frequently misdiagnosed as chronic dermatitis. Clinicians must consider:
* Vulvar Lichen Sclerosus: Usually features white, thinning skin rather than erythematous, weeping plaques.
* Candida Albicans Infection: Usually presents with satellite lesions and responds to antifungal therapy.
* Squamous Cell Carcinoma (SCC) In Situ: Lacks the classic "pagetoid" cells on histology.
* Melanoma (Amelanotic): Must be ruled out via HMB-45 or Melan-A staining if IHC results are ambiguous.

5. Risks, Prognosis, and Management

Surgical Management

Surgical excision remains the treatment of choice. The challenge lies in the "subclinical spread," where the visible lesion significantly underestimates the microscopic extent of the disease.
* Wide Local Excision (WLE): Standard approach with margins of at least 1–2 cm.
* Mohs Micrographic Surgery: Increasingly utilized to achieve clear margins while sparing healthy tissue, particularly in cosmetically sensitive areas.

Risks and Side Effects

• Recurrence: Extremely high (up to 30–50%), even with apparently clear margins.
• Invasive Progression: If the disease progresses to invasive adenocarcinoma, the prognosis worsens significantly, requiring radical vulvectomy and potentially lymph node dissection.
• Surgical Morbidity: Post-operative scarring, sexual dysfunction, and wound breakdown.

Long-term Prognosis

Patients with intraepithelial disease have an excellent 5-year survival rate (near 100%). However, patients with invasive VPD have a guarded prognosis, with survival highly dependent on the depth of invasion and the presence of lymph node involvement. Long-term surveillance (clinical exams every 6 months) is mandatory.

6. Frequently Asked Questions (FAQ)

1. Is Vulvar Paget Disease a form of skin cancer?
Yes, it is a rare form of intraepithelial adenocarcinoma, meaning it is a cancer that begins in the superficial layers of the skin.

2. Can Vulvar Paget Disease be cured with creams?
Topical treatments (like Imiquimod or 5-Fluorouracil) are sometimes used for patients who are not candidates for surgery, but they are generally considered second-line and have high recurrence rates.

3. Why is it so often misdiagnosed?
Because the symptoms (itching, redness) are identical to common yeast infections, eczema, or psoriasis. It is often treated with steroids for months before a biopsy is performed.

4. Does every patient with VPD need a colonoscopy?
Not necessarily. If the IHC profile confirms Primary VPD, the risk of an internal malignancy is low. However, if the IHC is consistent with a secondary source, a full gastrointestinal and urological workup is mandatory.

5. How far do the margins need to be?
Because of the "skip lesions" and microscopic spread, surgeons typically aim for 1–2 cm clear margins.

6. Is this disease related to HPV?
Unlike many other vulvar cancers, Vulvar Paget Disease is generally not associated with Human Papillomavirus (HPV) infection.

7. Can I have sexual intercourse after treatment?
Yes, but healing time is required. If the excision was extensive, pelvic floor physical therapy may be recommended.

8. Is there a genetic component?
There is no strong evidence of a hereditary link for VPD. It is typically a sporadic, non-hereditary condition.

9. How frequent should my follow-up visits be?
Due to the high recurrence rate, patients are typically followed every 3–6 months for the first two years, and annually thereafter.

10. What are the signs of recurrence?
Any return of persistent itching, new redness, or a "weeping" sore in the area that was previously treated should be biopsied immediately.

7. Clinical Summary Table: Management Strategy

Final Note to Clinicians

Vulvar Paget Disease is a "great mimicker." A low threshold for biopsy is the most critical tool in the clinician’s arsenal. If a patient presents with a chronic, eczematous vulvar lesion that has failed 4–6 weeks of standard topical dermatological treatment, a punch biopsy is not merely recommended—it is the standard of care. Early detection of primary disease is curative; failure to diagnose the underlying secondary disease can be fatal.